[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2330132T3 - Antistoffer mod MMP2 eller MMP9 og farmaceutiske sammensætninger deraf til hæmning af deres metalloproteinaktivitet - Google Patents

Antistoffer mod MMP2 eller MMP9 og farmaceutiske sammensætninger deraf til hæmning af deres metalloproteinaktivitet

Info

Publication number
DK2330132T3
DK2330132T3 DK10013205.9T DK10013205T DK2330132T3 DK 2330132 T3 DK2330132 T3 DK 2330132T3 DK 10013205 T DK10013205 T DK 10013205T DK 2330132 T3 DK2330132 T3 DK 2330132T3
Authority
DK
Denmark
Prior art keywords
mmp2
mmp9
antibodies
inhibit
pharmaceutical compositions
Prior art date
Application number
DK10013205.9T
Other languages
English (en)
Inventor
Irit Sagi
Tamar Danon
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK2330132T3 publication Critical patent/DK2330132T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK10013205.9T 2003-04-04 2004-04-04 Antistoffer mod MMP2 eller MMP9 og farmaceutiske sammensætninger deraf til hæmning af deres metalloproteinaktivitet DK2330132T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46000503P 2003-04-04 2003-04-04
EP04725641A EP1610678B1 (en) 2003-04-04 2004-04-04 Antibodies for inhibiting the activity of mmp-2 and mmp-9

Publications (1)

Publication Number Publication Date
DK2330132T3 true DK2330132T3 (da) 2013-11-04

Family

ID=33131910

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10013205.9T DK2330132T3 (da) 2003-04-04 2004-04-04 Antistoffer mod MMP2 eller MMP9 og farmaceutiske sammensætninger deraf til hæmning af deres metalloproteinaktivitet
DK04725641.7T DK1610678T3 (da) 2003-04-04 2004-04-04 Antistoffer til inhibering af aktiviteten af MMP-2 og MMP-9

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04725641.7T DK1610678T3 (da) 2003-04-04 2004-04-04 Antistoffer til inhibering af aktiviteten af MMP-2 og MMP-9

Country Status (6)

Country Link
US (4) US7524938B2 (da)
EP (2) EP2330132B1 (da)
AT (1) ATE517926T1 (da)
DK (2) DK2330132T3 (da)
ES (2) ES2369498T3 (da)
WO (1) WO2004087042A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524938B2 (en) * 2003-04-04 2009-04-28 Yeda Research And Development Co., Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
CA2595395A1 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
JP2009522302A (ja) 2005-12-30 2009-06-11 ダイアックス コーポレーション マトリックスメタロプロテイナーゼ結合タンパク質
CA2678304A1 (en) * 2007-02-23 2008-08-28 Yeda Research And Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
US8536313B2 (en) 2007-07-10 2013-09-17 Shionogi & Co., Ltd. Monoclonal antibody having neutralizing activity against MMP13
KR20100071972A (ko) * 2007-08-15 2010-06-29 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Ｍｍｐ-9의 조절인자 및 그의 용도
CA2707637A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
US8183008B2 (en) * 2007-12-17 2012-05-22 Dyax Corp. Evaluating MMP expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
EP2262529A4 (en) 2008-03-03 2013-05-08 Dyax Corp METALLOPROTEINASE BINDING PROTEINS 9
US8013125B2 (en) * 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
US20110236395A1 (en) * 2008-09-09 2011-09-29 University Of East Anglia Treatment of fibrotic eye disorders using an mmp2 inhibitor
CN101559076B (zh) * 2009-05-27 2012-08-29 西北大学 抗肿瘤基质金属蛋白酶抑制剂
US8697078B2 (en) 2010-01-27 2014-04-15 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
PT2608809T (pt) * 2010-08-27 2019-08-26 Gilead Biologics Inc Anticorpos para a metaloproteinase 9 da matriz
ES2688457T3 (es) 2010-10-28 2018-11-02 Yeda Research And Development Co. Ltd. Métodos de generación de anticuerpos contra metaloenzimas
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
DK2809350T3 (da) 2012-01-30 2019-01-28 Arecor Ltd Stabiliserede vandige antistofpræparater
JP6144286B2 (ja) * 2012-02-29 2017-06-07 ギリアード バイオロジックス， インコーポレイテッド マトリックスメタロプロテイナーゼ９に対する抗体
JP7109440B2 (ja) 2017-07-18 2022-07-29 第一三共株式会社 活性型ｍｍｐ－９結合ペプチド
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4595700A (en) 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4743587A (en) 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5239078A (en) 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5189178A (en) 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
EP0634998B1 (en) 1992-04-07 1997-03-19 British Biotech Pharmaceuticals Limited Hydroxamic acid based collagenase and cytokine inhibitors
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5679548A (en) 1993-02-02 1997-10-21 The Scripps Research Institute Methods for producing polypeptide metal binding sites and compositions thereof
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
US5800814A (en) 1994-04-22 1998-09-01 Oklahoma Medical Research Foundation Method for inhibition of breast tumor growth
WO1995029689A1 (en) 1994-04-28 1995-11-09 Merck & Co., Inc. N-carboxyalkyl derivatives as antidegenerative active agents
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
US5629980A (en) * 1994-11-23 1997-05-13 Xerox Corporation System for controlling the distribution and use of digital works
US6022893A (en) 1995-08-08 2000-02-08 Ono Pharmaceutical Co., Ltd. Hydroxamic acid derivatives
EP0780386B1 (en) 1995-12-20 2002-10-02 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors
AU1529897A (en) 1996-01-02 1997-07-28 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
KR20000022532A (ko) 1996-06-27 2000-04-25 오노 야꾸힝 고교 가부시키가이샤 아릴(설파이드, 설폭시드 및 설폰)유도체 및 이를 활성 성분으로 함유하는 약물
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP3673888B2 (ja) 1998-03-09 2005-07-20 独立行政法人科学技術振興機構 ポルフィリン類金属錯体の製造方法
SK1192001A3 (en) 1998-07-30 2002-02-05 Warner Lambert Co Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
WO2003006006A1 (en) * 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
WO2003044058A2 (en) * 2001-11-23 2003-05-30 Universite Catholique De Louvain Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis
US7524938B2 (en) * 2003-04-04 2009-04-28 Yeda Research And Development Co., Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins

Also Published As

Publication number Publication date
EP1610678A4 (en) 2008-04-09
ES2369498T3 (es) 2011-12-01
US20070172482A1 (en) 2007-07-26
WO2004087042A2 (en) 2004-10-14
EP1610678B1 (en) 2011-07-27
EP2330132B1 (en) 2013-08-14
US20140370031A1 (en) 2014-12-18
EP2330132A1 (en) 2011-06-08
US8841108B2 (en) 2014-09-23
US20090208510A1 (en) 2009-08-20
EP1610678A2 (en) 2006-01-04
US20120003236A1 (en) 2012-01-05
US7524938B2 (en) 2009-04-28
WO2004087042A3 (en) 2005-07-14
DK1610678T3 (da) 2011-10-24
ES2433440T3 (es) 2013-12-11
ATE517926T1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
DK2330132T3 (da) Antistoffer mod MMP2 eller MMP9 og farmaceutiske sammensætninger deraf til hæmning af deres metalloproteinaktivitet
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
FR14C0064I2 (fr) Anticorps anti-il-6, compositions, methodes et utilisations associees
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
CY1119106T1 (el) Αντισωματα εναντι masp-2
DK1583774T3 (da) Fremgangsmåder til forebyggelse og behandling af alzheimers sygdom
CY1110322T1 (el) Αναστολεις της her3 δραστικοτητας
BRPI0507856A (pt) composição farmacêutica, e, processo para preparar o anticorpo abeta
UA114604C2 (uk) Антитіло, яке зв'язується з людською пропротеїнконвертазою субтилізин/кексинового типу 9 (pcsk9)
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
DK1487485T3 (da) Imidazoquinolinadjuvanser til DNA-vacciner
EA200901500A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
NO20035488D0 (no) HV-protease-inhibitorer, blandinger inneholdende disse, deres farmas degree ytiskeanvendelser og materialer for deres syntese
CY1115871T1 (el) Μεθοδοι για την αντιμετωπιση ουρικης αρθριτιδας
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
DK1406656T3 (da) Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
DK1851250T3 (da) Humant monoklonalt antistof mod prostataspecifikt membranantigen (psma)
DK1636561T3 (da) Kombinatorisk proteinbiblioteksscreening ved hjælp af periplasmatisk ekspression
ATE339501T1 (de) Positionsabhängige erkennung des gnn nucleotidtripletts durch zinkfinger
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
DE60331598D1 (de) Verabreichung von anti-tnf-alpha f(ab')2 antikörper-fragmenten
DK1267925T3 (da) Behandling af svampeinfektion mod antifungale polyener eller beta-glucansyntesehæmmere kombineret med anti-hsp90-antistoffer
EA200700108A1 (ru) Новое применение пептидных соединений для лечения идиопатического тремора и других синдромов, ассоциированных с тремором